Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17929495 | 0.93 | PDK2 (0.38) | PDK2ESR1ESR2PTPRCKDM4E | |
| SCHEMBL20218273 | 0.92 | PDK2 (0.35) | PDK2ESR1ESR2KDM4EMEN1 | |
| SCHEMBL20218474 | 0.92 | PDK2 (0.36) | PDK2ESR1ESR2PTPRC | |
| SCHEMBL19218267 | 0.91 | KDM4E (0.37) | PDK2ESR1ESR2KDM4EMEN1 | |
| SCHEMBL19218359 | 0.91 | KDM4E (0.37) | PDK2ESR1ESR2KDM4EMEN1 | |
| SCHEMBL19218254 | 0.90 | KDM4E (0.38) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL19167798 | 0.90 | PDK2 (0.43) | PDK2ESR1ESR2PTPRCKDM4E | |
| SCHEMBL15892500 | 0.88 | PDK2 (0.42) | PDK2ESR1ESR2PTPRCKDM4E | |
| SCHEMBL19218896 | 0.88 | PDK2 (0.41) | PDK2ESR1ESR2PTPRC | |
| SCHEMBL17929496 | 0.88 | PDK2 (0.35) | PDK2ESR1ESR2PTPRCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10991886-B2 | Amine-based compound and organic light emitting device comprising same | LG CHEM, LTD. | 2021-04-27 | — | — | US | disclosed |
| EP-3330249-B1 | AMINE-BASED COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEMICAL LTD (KR) | 2021-01-06 | — | — | EP | disclosed |
| EP-3330249-A1 | AMINE-BASED COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG Chem, Ltd. (KR) | 2018-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10991886-B2 | Amine-based compound and organic light emitting device comprising same | TYR, PNMT, AOC2 | PDK2 2736/4885ESR1 63/4885ESR2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.